A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention

NCT00271401 Phase 3 COMPLETED

The purpose of this study is to compare the effectiveness and safety of intracoronary stenting with or without abciximab, an anti-platelet therapy, and conventional coronary angioplasty with abciximab in patients undergoing percutaneous coronary intervention.

Details

Lead sponsor	Centocor, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	2399
Start date	1996-07
Completion	1997-09

Conditions

• Angioplasty, Transluminal, Percutaneous Coronary

Interventions

• Angioplasty
• Intracoronary Stent
• Abxicimab
• Heparin
• Placebo

Primary outcomes

• Number of Participants With any one of these: Deaths, Myocardial Infarctions, or Urgent Repeat Revascularizations — Up to 30 days